These data suggested that the increased Akt and ERK activities in response to CSE and B[α]P treatment may result from an alternative signaling and thereby contribute to the insensitivity of wtEGFR‐expressing smoker NSCLC patients to EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.